Vorasidenib
As of the edition of 20 October 2026, Vorasidenib is a small molecule: marketed, first approved in 2024 (US); acts on IDH1 and IDH2; US protection ends in 2039.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2025
- Kind
- Small molecule
- Brand name
- Voranigo
- First approved
- 6 August 2024 (US)
- Approvals on record
- 6 in 4 regions
- Holder of the most recent approval
- Nihon Servier Co., Ltd.; 4 holders in all
- Registered trials
- 24, 0 stopped early
- Disease areas
- Cancer; Blood and lymph; Immune system; Nervous system
US protection
US protection ends in 2039.
The last listed US drug-substance patent ends in 2039. The application that gives this date is held by Servier.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product10 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 10 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
1 company-target row on route B because of this drug.
Companies on route B for this drug
In the product1 company-target row is on route B because of Vorasidenib.
See the 1 company-target row on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 4 | 0 | 3 | 0 |
| Phase 1 | 14 | 11 | 3 | 0 |
| Phase 2 | 2 | 0 | 2 | 0 |
| Phase 3 | 4 | 0 | 4 | 0 |
| All trials | 24 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Servier | Originator, Applicant and Lead sponsor of trials | 2023 to now |